BridgeBio Achieves Landmark Phase 3 Results With Infigratinib—First Statistically Significant Gains in Body Proportionality for Achondroplasia
Market Chameleon (Thu, 12-Feb 11:12 AM)
BridgeBio’s Oral Infigratinib Achieves First Statistically Significant Improvements in Body Proportionality for Achondroplasia in Phase 3 Trial
Market Chameleon (Thu, 12-Feb 7:58 AM)
BridgeBio’s Upcoming Achondroplasia Webinar Set to Highlight Advancements in Skeletal Dysplasia Research
Market Chameleon (Fri, 2-Jan 9:01 AM)
